GUAM International Consensus Guideline on GU Adverse Events
ForProstate cancer pts receiving RT, intact gland or post-prostatectomy
TL;DRFirst RT-specific GU AE guideline: 48-expert Delphi, 31 key questions; 76% favor moderate hypofractionation over SBRT at baseline IPSS 15-19.
Reported via UroToday →
Baseline IPSS, not a bladder or urethral constraint, becomes the gating variable for fractionation: 76% favored moderate hypofractionation over SBRT at IPSS 15-19, while no dose-volume constraint reached consensus. The technique lever the panel flagged is margin, citing MIRAGE late G≥2 GU 51% to 27% with 2-mm MRI-guided vs 4-mm CT-guided margins.
In an intact-prostate pt with severe obstructive LUTS before RT, this supports urology referral for an outlet procedure with an 8-12 week recovery interval before RT; it does not extend to irritative-predominant symptoms, where 95% of the panel advised against a prophylactic procedure.
Baseline IPSS is the gating variable for fractionation: 76% favored moderate hypofractionation over SBRT at IPSS 15-19, and 85% endorse full bladder at sim and treatment. No dose-volume constraint reached consensus, so margin reduction (MIRAGE 2-mm vs 4-mm) is the cited technique lever.
The surgical decision is timing and selection of an outlet procedure: 74% would refer at IPSS ≥20, 94% would wait ≥8 wk and 66% ≥12 wk before RT. 95% advise against a prophylactic procedure when irritative symptoms predominate, and only 52% consider SBRT safe afterward.
15 details
Systematic review (183 articles) plus a 3-round modified Delphi, May 2025 to Feb 2026, consensus defined as ≥75% agreement. Panel of 48 experts from 15 countries (34 radonc, 7 medonc, 7 urologic onc); 31 key questions reached consensus. Independently peer reviewed, endorsed by ASTRO and ESTRO.
76% favor moderate hypofractionation over SBRT at baseline IPSS 15-19; 85% recommend a full bladder at simulation and treatment. No dose-volume constraint reached consensus. After a BOO procedure, only 52% considered SBRT safe once obstruction resolved.
Intact gland: alpha blocker 1st-line for obstructive, anti-spasmodic 1st-line for irritative symptoms; anti-spasmodic 1st-line post-prostatectomy. 80% against prophylaxis before symptom onset; 80% add a 2nd agent rather than switch.
Cites MIRAGE: 2-mm MRI-guided margins cut late G≥2 GU AEs from 51% to 27% vs 4-mm CT-guided. CHHiP, PROFIT, RTOG 0415 and the HYDRA meta-analysis did not show a consistent late GU increase with moderate hypofractionation; RICH-ART supports HBOT for refractory radiation cystitis.
Several reported splits (74% for post-op alpha blocker futility and IPSS ≥20 referral, 52% for post-procedure SBRT) sit under the ≥75% bar and the write-up does not say how they were adopted. Radonc-heavy panel (34 of 48). Trade-press summary, not the manuscript.
Formalizes practice previously extrapolated from BPH and OAB data and moves fractionation choice onto baseline IPSS. Open gaps: dose-volume constraints, urethral contouring reliability, and RT-specific drug evidence; BEFORE, RadTARGET, RELIEF and DESTINATION-2 are ongoing, and the guideline is meant to be living.
| Setting | Preferred 1st-line | Subsequent options, in order |
|---|---|---|
| Intact, obstructive | Alpha blocker | PDE5-I → NSAID → steroid → anti-spasmodic |
| Intact, irritative | Anti-spasmodic | Alpha blocker → NSAID → phenazopyridine → cranberry |
| Post-prostatectomy | Anti-spasmodic | Not stated in source |
| Baseline IPSS | % panel selecting |
|---|---|
| 10-14 | 16% |
| 15-19 | 61% |
| 20-24 | 21% |
| ≥25 | 2% |
| Baseline IPSS | % panel selecting |
|---|---|
| 15-19 | 34% |
| 20-24 | 47% |
| 25-29 | 15% |
| ≥30 | 4% |
Modified Delphi guideline on a systematic review; recommendations are panel agreement, not outcomes, and several reported thresholds fall at or below the stated ≥75% consensus bar.
- Which dose-volume constraints predict late GU toxicity?
- Reliability of urethral contouring for prostate RT
- RT-specific evidence for alpha blockers and anti-spasmodics
📚 Sources · 📄 1 paper
Abstract
The longer read
The value of this guideline is less in any single recommendation than in where it places the decision weight. Most of the acute medication algorithm will look familiar to anyone treating prostate cancer: an alpha blocker for obstructive symptoms in an intact gland, an anti-spasmodic for irritative symptoms or after prostatectomy. Until now that practice was borrowed from BPH and overactive bladder populations, and the panel is candid that the RT-specific evidence for many of these drugs remains thin. Codifying it does not make it evidence-based; it makes it consistent, which is a reasonable goal for a supportive-care problem affecting more than 30% of men acutely.
The more consequential move is on technique. The panel converged on baseline IPSS as the variable that should steer fractionation, with 76% favoring moderate hypofractionation over SBRT at an IPSS of 15-19, while failing to agree on any dose-volume constraint. That asymmetry is informative. It says the field trusts a validated symptom score more than any bladder or urethral metric it currently plans to, which is an honest reflection of how poorly organ dose has predicted GU toxicity. The cited hypofractionation trials (CHHiP, PROFIT, RTOG 0415, and the HYDRA meta-analysis) did not show a consistent late GU penalty with moderate hypofractionation, so the preference for it over SBRT in symptomatic glands is a caution about ultrahypofractionation in a vulnerable subset rather than a finding that moderate schedules are safe in general. Readers should note that the IPSS threshold itself was not a clean consensus: 61% picked the 15-19 band and the single-threshold ≥15 drew 60%.
The margin argument rests largely on MIRAGE, where 2-mm MRI-guided margins were associated with late G≥2 GU events falling from 51% to 27% versus 4-mm CT guidance. That is a single-center randomized result, and translating it into a general margin recommendation depends on image guidance most departments do not run. The direction is plausible; the magnitude in a CT-guided practice is unknown.
Methodologically, the guideline inherits the usual Delphi limits, plus two specific ones. First, several reported splits, including the 74% for post-prostatectomy alpha blocker futility and for referral at IPSS ≥20, and 52% for SBRT after an outlet procedure, sit under the stated 75% bar; the trade-press account does not clarify whether these became recommendations or remained reported opinion, and a reader should treat them as the latter until the manuscript says otherwise. Second, the panel is weighted toward radiation oncology (34 of 48), which matters most for the outlet procedure questions where urologic judgment carries the procedural risk.
What would make this wrong is a prospective dataset showing that a urethral or bladder dose constraint predicts late GU toxicity better than baseline IPSS, or that SBRT in IPSS 15-19 glands with modern margins carries no excess toxicity. The ongoing trials named (BEFORE, RadTARGET, RELIEF, DESTINATION-2) are positioned to address parts of that, and the working group frames the document as living. For now it is best read as a standardized default for symptomatic men, not a constraint set.